The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Genomic therapy matching in rare and refractory cancers: Updated results from a retrospective cohort study in the Molecular Screening and Therapeutic (MoST) program.
 
Frank Po-Yen Lin
No Relationships to Disclose
 
Subotheni Thavaneswaran
Research Funding - AstraZeneca (Inst); Elevation Oncology (Inst); Roche/Genentech (Inst)
 
Christine E Napier
No Relationships to Disclose
 
John P. Grady
No Relationships to Disclose
 
Maya Kansara
No Relationships to Disclose
 
Lucille Sebastian
Research Funding - AstraZeneca/MedImmune (Inst); Merck KGaA (Inst); Roche (Inst)
 
Damien Kee
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene; MSD; Novartis
 
Milita Zaheed
No Relationships to Disclose
 
Michael Millward
Consulting or Advisory Role - Amgen; AstraZeneca; BeiGene; Bristol-Myers Squibb; Guardant Health; IQvia; Lilly; Merck Serono; Novartis; Pfizer; Roche; The Limbic
Research Funding - Abbvie (Inst); Akeso Biopharma (Inst); Albion Laboratories (Inst); Alpine Immune Sciences (Inst); Amgen (Inst); Apollomics (Inst); AstraZeneca (Inst); AtriCure (Inst); Axelia Oncology (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); CStone Pharmaceuticals (Inst); Cullinan Oncology (Inst); Dizal Pharma (Inst); Eucure Biopharma (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); Genfleet Therapeutics (Inst); GlaxoSmithKline (Inst); IMPAC Medical Systems (Inst); InventisBio (Inst); InxMed (Inst); Kinnate Biopharma (Inst); Lilly (Inst); Maxinovel (Inst); Relay Therapeutics (Inst); Turning Point Therapeutics (Inst); Tyra Biosciences (Inst); Vivace Therapeutics (Inst)
 
Michael Paul Brown
Honoraria - BMS Australia (Inst); MSD Oncology (Inst); Novartis (Inst)
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Cartherics; Currus Biologics; Merck Sharp & Dohme (Inst); Novartis (Inst)
Research Funding - Bristol-Myers Squibb (Inst); CStone Pharmaceuticals (Inst); Merck Sharp & Dohme (Inst); Pharmaust (Inst); Zucero Therapeutics (Inst)
 
Michail Charakidis
No Relationships to Disclose
 
Paul Stanley Craft
Stock and Other Ownership Interests - Cochlear; CSL Limited; Pro Medicus
 
Peter S. Grimison
Research Funding - Daiichi Sankyo Europe GmbH (Inst); Daiichi Sankyo Europe GmbH (Inst); Eisai (Inst); Epizyme (Inst); Genentech (Inst); Janssen-Cilag (Inst); Medimmune; MSD (Inst); Pfizer (Inst); Pfizer (Inst); PTC Therapeutics (Inst); PTC Therapeutics (Inst); QED Therapeutics (Inst); Tilray (Inst)
 
Rosemary A. Harrup
No Relationships to Disclose
 
Kenneth John O'Byrne
Stock and Other Ownership Interests - Carpe Vitae Pharmaceuticals; DGC diagnostics; RepLuca Pharmaceuticals
Honoraria - Amgen; Astrazeneca; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Ipsen; Janssen-Cilag; Merck; Merck Sharp & Dohme; Novartis; Pfizer/EMD Serono; Roche; Takeda; TriStar Technology Group; Yuhan
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Ipsen; Janssen-Cilag; Merck Sharp & Dohme; Novartis; Pfizer; Roche/Genentech; Sanofi; Yuhan
Speakers' Bureau - Boehringer Ingelheim; Bristol-Myers Squibb; Janssen-Cilag; Merck; Merck Sharp & Dohme; Pfizer; Roche
Patents, Royalties, Other Intellectual Property - I am named on 4 active patents, 2 published and 2 provisional (Inst)
 
Jayesh Desai
Consulting or Advisory Role - Amgen (Inst); Bayer; BeiGene; Boehringer Ingelheim; Daiichi Sankyo Europe GmbH; GlaxoSmithKline; Merck KGaA; Novartis; Pfizer; Pierre Fabre; Roche/Genentech
Research Funding - AstraZeneca/MedImmune (Inst); BeiGene (Inst); Bionomics (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Novartis (Inst); Roche (Inst)
 
Chee Khoon Lee
Honoraria - Amgen; AstraZeneca; GlaxoSmithKline; Janssen Oncology; Merck KGaA; MSD Oncology; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Merck; Merck KGaA; Novartis; Pfizer; Takeda
Research Funding - Amgen; AstraZeneca (Inst); Merck KGaA (Inst); Roche (Inst)
 
Mandy L. Ballinger
Honoraria - Roche (I)
Research Funding - Amgen (I); AstraZeneca (I); Bayer (I); Elevation Oncology (I); George Clincal (I); Lilly (I); Microba (I); Pfizer (I); Roche (I); Seagen (I); Sun Pharma (I)
Travel, Accommodations, Expenses - Amgen (I)
 
John Simes
Consulting or Advisory Role - FivePhusion (Inst)
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Elevation Oncology (Inst); MSD (Inst); Pfizer (Inst); Roche (Inst)
 
David Morgan Thomas
Employment - Australian Unity
Honoraria - Roche
Research Funding - Amgen; AstraZeneca; Bayer; Elevation Oncology; George Clincal (Inst); InterVenn Biosciences; Lilly (Inst); Microba (Inst); Pfizer; Roche; Seagen (Inst); Sun Pharma (Inst)
Travel, Accommodations, Expenses - Amgen